The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

nxthera.com

Founded Year

2008

Stage

Acquired | Acquired

Total Raised

$122.9M

Valuation

$0000 

About NxThera

NxThera developed its Convective Water Vapor Energy (WAVE) technology platform to treat a variety of endourological conditions beginning with BPH. NxThera's FDA cleared Rezūm System to treat BPH uses radiofrequency energy to create sterile water vapor, or steam, to convectively deliver targeted, precise thermal energy treatments in a simple procedure with minimal discomfort, and provide improvements in LUTS symptoms, urine flow and quality of life. The Company is furthering the application of the technology platform through advanced research and development targeting the treatment of prostate cancer and kidney cancer.

NxThera Headquarter Location

7351 Kirkwood Lane N Suite 138

Maple Grove, Minnesota, 55369,

United States

763-515-0404

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NxThera

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NxThera is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

11,465 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health IT

7,900 items

NxThera Patents

NxThera has filed 21 patents.

The 3 most popular patent topics include:

  • Alpha blockers
  • Antiandrogens
  • Antigonadotropins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/19/2016

2/15/2022

Mammal male reproductive system, Penis, Andrology, Inflammations, Psychiatric diagnosis

Grant

Application Date

12/19/2016

Grant Date

2/15/2022

Title

Related Topics

Mammal male reproductive system, Penis, Andrology, Inflammations, Psychiatric diagnosis

Status

Grant

Latest NxThera News

Cold Disposable Biopsy Forceps Market is raising at a healthy CAGR of 8.4% during forecast period 2021-2031

Mar 11, 2022

Search jobs 11-Mar-2022 Cold Disposable Biopsy Forceps Market is raising at a healthy CAGR of 8.4% during forecast period 2021-2031 According to a recent study by Future Market Insights (FMI), the  cold disposable biopsy forceps market  is expected to witness high growth during the forecast period. The market value is slated to increase from US$ 505.1 Mn in 2020 to over US$ 1.2 Bn by 2031 at 8.4% CAGR over the forecast period (2021-2031). The cold disposable biopsy forceps market will register high demand due the rising prevalence bronchitis and gastrointestinal disorders such as IBD and GERD among the geriatric population and the increasing awareness towards endoscopic procedures. There is also a rise in the adoption of disposable biopsy forceps that to be reliable for test sampling expects to gain popularity. At present, the minimally-invasive technology, with the endoscope system at the core, has been extended to obstetrics, general surgery, otolaryngology, gynecology, thoracic surgery, urology, pediatrics, and other departments. Minimally-invasive endoscopic technology has become an indispensable technology for the diagnosis and treatment of chronic diseases associated with breathing, digestion, urology, otolaryngology, and so on. With the rising demand for endoscopic minimally-invasive technology and continuous improvement in endoscopic processing technology, endoscopic applications have become prominent in almost all departments. The growing demand for diagnosis and endoscopic treatment is expected to further boost the demand for cold disposable biopsy forceps. To remain ‘ahead’ of your competitors, request for a sample @  https://www.futuremarketinsights.com/reports/sample/REP-GB-14240 Numerous recent technological advances are becoming available to endoscopists. An abundance of new imaging modalities is expected to facilitate early detection of chronic disorders and other pathological entities. Most of these techniques remain investigational and are currently in clinical trials to determine patient benefits. Companies are expanding their product lines by manufacturing different types of products for a wide range of applications. For instance, Micro-Tech Endoscopy is mainly engaged in the R&D, manufacturing, and sales of minimally-invasive medical devices, in line with its mission of supporting clinicians with technology and innovation. Key Takeaways from Cold Disposable Biopsy Forceps Market Study Oval cup forceps gained popularity and their sales are expected to grow at a CAGR of 8.8% during the forecast period. 2.8 mm diameter have sharpened cups whch ensure superior cutting performance and lead to fewer artefacts and less bleeding. The segment is therefore expected to account for a share of 24.9% in 2021. 2300 mm length forceps has precise jaws, no tearing and cause small wound. The segment accounted for the highest share of 37.9% in 2021. Upper GI Endoscopy dominated the application segment with the highest market share of 24.9% in 2021. Hospitals accounted for the largest share of around 42.0% in 2021 and will remain the end user in the market. Who is winning? The key players are focusing on acquisitions and partnerships with small players and suppliers to increase their market presence. Besides this, they are adopting various strategies to expand their footprint. For instance: iIn April 2018, Boston Scientific Corporation closed its acquisition of NxThera. The company developed a minimally-invasive therapy the Rezūm system, for patients suffering from symptomatic benign prostatic hyperplasia. With the completion of the acquisition, NxThera became a part of Boston Scientific’s urology and pelvic health business. Moreover, the manufacturers are focusing on research and development activities for developing cold disposable biopsy forceps for various research applications. In july 2020, ChargePoint and STERIS collaborated to develop a fully validated sterile transfer solution to offer a unique and integrated solution for sterile product transfer. Some of the leading players in the cold disposable biopsy forceps market include but are not limited to Olympus Corporation, Boston Scientific Corporation, STERIS, CONMED Corporation, Cook Medical, Micro-Tech Endoscopy, Anrei Medical and other companies. For critical insights, request for PDF Brochure @  https://www.futuremarketinsights.com/reports/brochure/rep-gb-14240 Why Future Market Insights? • Detailed insights of market segments and sub-segments for historical as well as forecast period • A competitive analysis of prominent players and emerging players in the keyword market • Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario About FMI: Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact Us:

  • When was NxThera founded?

    NxThera was founded in 2008.

  • Where is NxThera's headquarters?

    NxThera's headquarters is located at 7351 Kirkwood Lane N, Maple Grove.

  • What is NxThera's latest funding round?

    NxThera's latest funding round is Acquired.

  • How much did NxThera raise?

    NxThera raised a total of $122.9M.

  • Who are the investors of NxThera?

    Investors of NxThera include Boston Scientific, Arboretum Ventures, Aberdare Ventures, Apple Tree Partners, GDN Holdings and 13 more.

  • Who are NxThera's competitors?

    Competitors of NxThera include MicroTransponder, Ecochlor, Vertiflex, Articulinx, Advanced Biosurfaces and 12 more.

You May Also Like

A
Articulinx

Articulinx, Inc is developing minimally invasive implants for the treatment of osteo-arthritis.

D
DuoCore

DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.

V
Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

N
Neocrin

Researcher and developer of a minimally invasive, encapsulated cellular transplant device for the treatment of diabetes. The company sold its assets to Novocell.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.

E
Emphasys Medical

Emphasys Medical has developed an innovative device called the Emphasys Endobronchial Valve* (EBV). The EBV is implanted in the diseased portions of the lung and utilizes a one-way valve to prevent air from entering the diseased lung segments during inhalation yet allows trapped air to vent during exhalation. This design is intended to allow inhaled air to be redirected to the healthier, functional parts of the lung. The Emphasys procedure is a minimally invasive treatment option in which the device is placed in selectively targeted areas of the affected lung determined by the extent of the emphysema damage.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.